D. E. Shaw & Co. Inc. decreased its holdings in shares of TriMas Co. (NASDAQ:TRS - Free Report) by 21.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 110,546 shares of the industrial products company's stock after selling 29,809 shares during the period. D. E. Shaw & Co. Inc. owned about 0.27% of TriMas worth $2,718,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds also recently bought and sold shares of the company. Sterling Capital Management LLC boosted its holdings in shares of TriMas by 815.5% during the 4th quarter. Sterling Capital Management LLC now owns 1,300 shares of the industrial products company's stock valued at $32,000 after purchasing an additional 1,158 shares during the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of TriMas during the fourth quarter valued at approximately $202,000. Quantbot Technologies LP boosted its stake in TriMas by 203.5% in the fourth quarter. Quantbot Technologies LP now owns 11,978 shares of the industrial products company's stock valued at $295,000 after acquiring an additional 8,031 shares in the last quarter. Aquatic Capital Management LLC purchased a new position in shares of TriMas in the fourth quarter worth $359,000. Finally, MetLife Investment Management LLC raised its holdings in shares of TriMas by 5.9% in the fourth quarter. MetLife Investment Management LLC now owns 24,788 shares of the industrial products company's stock worth $610,000 after buying an additional 1,378 shares during the last quarter. Institutional investors own 99.42% of the company's stock.
Wall Street Analysts Forecast Growth
A number of research analysts have weighed in on TRS shares. Wall Street Zen cut shares of TriMas from a "buy" rating to a "hold" rating in a report on Saturday. BWS Financial reissued a "buy" rating and issued a $40.00 price target on shares of TriMas in a research note on Wednesday, April 30th.
Read Our Latest Analysis on TriMas
TriMas Stock Performance
NASDAQ:TRS traded down $0.66 during trading hours on Friday, reaching $25.42. 241,976 shares of the company's stock were exchanged, compared to its average volume of 332,619. The firm has a market capitalization of $1.03 billion, a price-to-earnings ratio of 39.72 and a beta of 0.58. The company has a 50-day moving average of $23.01 and a 200 day moving average of $24.02. The company has a quick ratio of 1.44, a current ratio of 2.83 and a debt-to-equity ratio of 0.60. TriMas Co. has a 1-year low of $19.33 and a 1-year high of $28.51.
TriMas (NASDAQ:TRS - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The industrial products company reported $0.46 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.43 by $0.03. TriMas had a net margin of 2.93% and a return on equity of 9.21%. The business had revenue of $241.67 million during the quarter, compared to the consensus estimate of $235.41 million. During the same quarter last year, the firm posted $0.37 EPS. The business's revenue was up 6.4% compared to the same quarter last year. Research analysts anticipate that TriMas Co. will post 1.69 EPS for the current year.
TriMas Dividend Announcement
The business also recently announced a quarterly dividend, which was paid on Tuesday, May 13th. Investors of record on Tuesday, May 6th were issued a $0.04 dividend. The ex-dividend date was Tuesday, May 6th. This represents a $0.16 dividend on an annualized basis and a yield of 0.63%. TriMas's payout ratio is 20.78%.
Insider Activity at TriMas
In other TriMas news, CFO Scott A. Mell sold 2,218 shares of the company's stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $22.54, for a total value of $49,993.72. Following the completion of the sale, the chief financial officer now directly owns 26,288 shares of the company's stock, valued at approximately $592,531.52. This represents a 7.78% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Shawn Sedaghat purchased 72,937 shares of the business's stock in a transaction on Thursday, May 22nd. The stock was acquired at an average cost of $26.16 per share, with a total value of $1,908,031.92. Following the completion of the acquisition, the director now directly owns 1,883,758 shares in the company, valued at $49,279,109.28. The trade was a 4.03% increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders purchased 1,772,695 shares of company stock worth $43,788,704. 14.20% of the stock is owned by company insiders.
About TriMas
(
Free Report)
TriMas Corporation engages in the design, development, manufacture, and sale of products for consumer products, aerospace, and industrial markets worldwide. The company operates through Packaging, Aerospace, and Specialty Products segments. The Packaging segment offers dispensing products, such as foaming and sanitizer pumps, lotion and hand soap pumps, beverage dispensers, perfume sprayers, and nasal and trigger sprayers; polymeric and steel caps and closures comprising food lids, flip-top and beverage closures, child resistance caps, drum and pail closures, and flexible spouts; polymeric jar products; integrated dispensers; bag-in-box products; and consumable vascular delivery and diagnostic test components under the Rieke, Taplast, Affaba & Ferrari, Intertech, Omega, and Rapak brands.
See Also

Before you consider TriMas, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TriMas wasn't on the list.
While TriMas currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report